TLDR:
- VenBio raises $528 million for fifth life sciences VC fund
- Fund V investors include sovereign wealth funds, corporate pensions, and more
VenBio, a veteran venture capital firm, has raised $528 million for its fifth life sciences investment fund. The fundraising began mid-April and attracted diverse investors from various sectors. The firm, based in San Francisco, focuses on investing in biotechs working on diseases with unmet needs and is interested in all stages of clinical development. VenBio has a successful track record of investing in companies that have been acquired or gone public, such as Aragon Pharmaceuticals and Seragon Pharmaceuticals. Fund V aims to maintain consistency in strategy, team, and investment discipline.
